CN117777286A - Antibody A4D7 targeting procalcitonin and application thereof - Google Patents

Abstract

The invention provides a procalcitonin-targeted antibody A4D7 and application thereof. The amino acid sequences of the light chain and the heavy chain of the antibody A4D7 are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 2. The antibody is used for developing a lateral flow immunochromatography detection reagent. The antibody has high sensitivity and good specificity, and has wide application prospect in the immunodiagnosis field.

Description

Antibody A4D7 targeting procalcitonin and application thereof

Technical Field

The invention relates to the technical field of immunodetection, in particular to a procalcitonin targeting antibody A4D7 and application thereof.

Background

Procalcitonin (PCT), a non-hormone-active glycoprotein consisting of 116 amino acids, is a precursor of Calcitonin (CT). PCT was found in tumor marker studies in the 80 th century. In the 90 s of the 20 th century, a dramatic increase in serum PCT index was found in patients with sepsis and septic shock in studies with markers of acute lung injury. The subject is introduced to discuss whether a relationship exists between PCT and infection, and subsequent studies indicate that PCT can be used as a serum marker for severe bacterial infection, particularly sepsis, is an important index for early assisted differential diagnosis of systemic inflammatory response, and can be used as an important index for judging disease severity, therapeutic effect and prognosis.

PCT is involved in immunomodulation as a clinical application for inflammation detection index:

PCT is one of the most commonly used markers for detecting inflammation as an immunomodulatory protein. PCT induction is tightly regulated by the body and its activation steps are highly correlated in both time and function, which correlation may be used to reflect the severity of the disease. Under physiological conditions PCT is synthesized by thyroid follicular side cells. In the presence of bacterial infection, cells in other parts of the body (e.g., monocytes and neuroendocrine cells) activate the induced expression of the procalcitonin corresponding CALC-I gene upon cytokine stimulation, thereby causing the continuous expression and release of PCT. In addition, PCT is very stable in vitro and in vivo, is easy to detect, and its increase in concentration is not susceptible to the immunosuppressive state of the body. As such, PCT is considered as a biomarker that plays an important role in early detection of systemic inflammatory response, and thus is widely used for differential diagnosis of various clinical symptoms including bacterial infectious diseases, judgment of disease conditions, and evaluation of prognosis, including but not limited to major wounds (accidental wounds, surgery, burns), multiple organ insufficiency, severe pancreatitis, or severe liver disease or kidney disease, neonatal early stage. In addition, non-infectious PCT elevations may be associated with severe tissue damage, elevated plasma pro-inflammatory cytokine levels, severe organ environmental disorders, or paraneoplastic syndromes, among other factors. PCT has high sensitivity and specificity for distinguishing infectious and non-infectious fever (e.g. tumor fever, drug fever). Lymphoma patients are susceptible to severe infections following chemotherapy due to immune dysfunction and granulocytopenia. Studies have shown that the PCT level of patients with granulocytopenia accompanied by obvious infection and fever is obviously increased, while the PCT level of patients with focal infection or fever of unknown origin is not obviously changed, and the study provides a reference for early diagnosis of bacterial blood flow infection and prevention of overuse of antibiotics.

Standardized detection method of PCT:

PCT half-life is 25-30h, and has good in vitro stability, convenient detection, and PCT concentration is reduced by about 12% after 24h of blood sampling at room temperature. The reduction in storage at 4℃is only 6%. Therefore, if the test cannot be performed immediately after the blood collection, the sample must be stored at a low temperature. The current PCT clinical detection method mainly comprises a chemiluminescent immunoassay method, a radioimmunoassay method, a colloidal gold method, a transmission immunoturbidimetry method, a time-resolved fluoroimmunoassay technology and the like, and the basic principle is the immunological binding reaction of an antigen and an antibody.

The detection method of the lateral chromatography rapid diagnosis kit can only provide qualitative results, is not suitable for specific pathogens (such as certain bacteria, mycoplasma, viruses and the like) needing to diagnose the infection condition according to fine quantitative results, and the lateral chromatography rapid diagnosis kit based on the time resolution fluorescence immunoassay technology has the characteristics of high sensitivity, convenient operation, high automation degree, standard curve width, no fluorescence interference of natural samples, simple and stable marker preparation, no radioactive pollution and the like on the premise of using specific instruments and using the specific antibody chemical markers (such as novel designs based on rare earth chelates and the like), and can be widely used for rapid detection or diagnosis. The concentration of the labeled antibody can be estimated by an immune reaction considering the use of a quantitative or semi-quantitative method, and the concentration of the bound target antigen can be estimated, so that a rapid diagnosis and a fine (semi-) quantification of a specific pathogenic microorganism can be theoretically achieved.

In any case, the lateral chromatography rapid diagnosis kit achieves the general standards of sensitivity, stability, economy and usability, and usually does not need the equipment required by rapid diagnosis, thus having important and wide practical value. These advantages of the lateral flow immunochromatographic rapid diagnostic kit are particularly important for units and areas lacking specialized equipment and untrained technicians, while new designs of corresponding products are still capable of meeting the fine quantitative or semi-quantitative requirements for units and areas having specialized equipment and trained technicians.

Disclosure of Invention

The invention aims to provide an antibody A4D7 targeting procalcitonin and application thereof.

To achieve the object of the present invention, in a first aspect, the present invention provides an antibody A4D7 targeting procalcitonin, which has the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of the light chain hypervariable regions RSSDSLLHSNGITYLF, QMSALAS and AQNLHLPWT, respectively, and the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of antibody M1301 of SDYSWE, YIDFRGSTKYNPSLRS and RGSFRY, respectively.

The amino acid sequences of the light chain and the heavy chain of the antibody are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 2.

In a second aspect, the invention provides the use of said antibody in the preparation of a procalcitonin detection reagent or kit.

In a third aspect, the invention provides procalcitonin detection reagents or kits prepared from the antibodies.

In a fourth aspect, the invention provides the use of the antibody in the preparation of a procalcitonin immunochromatographic test strip or a kit.

In a fifth aspect, the invention provides the use of said antibody in the preparation of a procalcitonin lateral flow immunochromatographic diagnostic kit.

In a sixth aspect, the invention provides a procalcitonin immunochromatography detection test strip, which comprises a sample pad, a combination pad, an NC film, a water absorption pad and a bottom plate, wherein a detection line and a quality control line are arranged on a reaction film, and the sample pad, the combination pad, the NC film and the water absorption pad are sequentially adhered to the bottom plate.

Wherein the binding pad is coated with an immune (fluorescent) microsphere coupled antibody F4B4 targeting procalcitonin; the detection line is coated with an antibody A4D7, and the quality control line is coated with goat anti-mouse polyclonal antibody.

The amino acid sequences of the light chain and the heavy chain of the antibody F4B4 are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4.

Preferably, the concentration of antibody F4B4 coated on the conjugate pad is 10-15 μg/mL.

Preferably, the concentration of the coated antibody A4D7 on the detection line is 1.5-2mg/mL.

Preferably, the sample pad and the water absorbing pad are made of cellulose, and the bonding pad is made of glass fiber.

In a seventh aspect, the invention provides a qualitative and (semi) quantitative rapid detection method of procalcitonin (comprising the non-diagnostic purpose), wherein the detection method is a double-antibody sandwich method, a first antibody is an antibody F4B4 targeting procalcitonin (the amino acid sequences of a light chain and a heavy chain of the first antibody are respectively shown as SEQ ID NO:3 and 4), and a second antibody is an antibody A4D7.

In the present invention, antibodies F4B4 and A4D7 bind to different epitopes of procalcitonin, respectively.

In the present invention, the corresponding antigenic amino acid sequence is an amino acid sequence which is correspondingly adjusted or modified, and the modification material comprises one or more of nano materials, fluorescent materials, enzymes, biotin and proteins. The method is favorable for applying the regulated or modified amino acid sequence to procalcitonin detection, procalcitonin immune antigen design and the like.

By means of the technical scheme, the invention has at least the following advantages and beneficial effects:

the invention provides an antibody A4D7 for targeting and recognizing procalcitonin, and the antibody A4D7 is used for constructing a lateral flow immunochromatography rapid diagnosis kit. The antibody has high specificity and high affinity characteristics, and one or more of the amino acid sequences are used as a core, so that the antibody is applied to design of a procalcitonin therapeutic target, and a therapeutic preparation aiming at procalcitonin can be designed, wherein the design of the therapeutic target comprises, but is not limited to, the design of a therapeutic antibody target.

The antibody can be effectively used for quantitative and/or qualitative detection of procalcitonin, can also be used for ELISA detection, immunochemistry detection, immunofluorescence detection and other detection methods, and has wide application range and strong applicability.

The rapid diagnosis kit based on lateral flow immunochromatography has the advantages of low detection limit and high sensitivity; and the selected antibody is specifically targeted to the epitope with the highly conserved amino acid sequence, so that the detection cost is reduced, the detection time is shortened, and the detection efficiency is improved. The lateral flow immunochromatography rapid diagnosis kit is a detection technology with important application value, and can realize the general standards of sensitivity, stability, economy, user friendliness, no need of equipment and the like required by rapid diagnosis. These advantages of the lateral flow immunochromatographic rapid diagnostic kit are of great importance, in particular for units or areas lacking professional equipment and lacking well-trained technicians.

Drawings

FIG. 1 shows the results of protein electrophoresis using purified recombinant PCT proteins in a preferred embodiment of the present invention.

FIG. 2 is a graph showing the binding of antibody A4D7 to recombinant procalcitonin antigen at gradient concentrations, respectively, according to the preferred embodiment of the present invention. Wherein 0.5. Mu.g (/ mL) is the binding curve of 50ng (100. Mu.L per well) of the coated antigen per well, and 1. Mu.g (/ mL) is the binding curve of 100ng (100. Mu.L per well) of the coated antigen per well.

FIG. 3 shows the results of a matched screening experiment of monoclonal antibodies in a preferred embodiment of the invention; wherein A is A4D7 and F4B4, B is A4D7 and A8E5, and C is A4D7 and C6H1.

FIG. 4 shows the results of examining the stability of the antibody A4D7 in the preferred embodiment of the present invention.

FIGS. 5 and 6 are graphs showing the results of detection (different dilutions) of a lateral flow immunochromatographic rapid test reagent developed based on an antibody of the present invention using a procalcitonin solution standard substance in a preferred embodiment of the present invention; fig. 5 shows the analysis results of the non-batch, and fig. 6 shows the analysis results of the batch.

Detailed Description

The following examples are illustrative of the invention and are not intended to limit the scope of the invention. Unless otherwise indicated, the technical means used in the examples are conventional means well known to those skilled in the art, and all raw materials used are commercially available. EXAMPLE 1 preparation of monoclonal antibody-producing hybridomas

1. Design, preparation and carrier coupling of procalcitonin antigen

Based on the information on the procalcitonin gene on GenBank (NM-001741.3,SEQ ID NO:5), the amino acid sequence of procalcitonin (SEQ ID NO: 6) was obtained. Through immunogenicity, hydrophilicity and hydrophobicity and surface accessibility analysis, the polypeptide sequence of 141 amino acids in the CDS region of procalcitonin is finally screened as antigen (figure 1), and the procalcitonin antigen is synthesized by self expression (the whole length of the gene is cloned on an expression vector pET20 b).

2. Immunized mice

After the synthetic antigen procalcitonin and Freund's complete adjuvant are uniformly mixed according to the ratio of 1:1 and emulsified by 500 mu L, 3 female Balb/c mice with the age of 6-8 weeks are subcutaneously injected in multiple points, the antigen inoculation dose of each mouse is 50 mu g, the antigen and Freund's incomplete adjuvant are uniformly mixed according to the ratio of 1:1 and emulsified by 500 mu L, the antigen inoculation dose of each mouse is 50 mu g, and the three weeks later, 50 mu g of the antigen is not added with adjuvant and is intraperitoneally injected for 4 times. The results are shown in Table 1:

TABLE 1 determination of the results of immunization of mice with the synthetic antigen procalcitonin

3. Immune serum potency assay

Immune serum titers were determined by indirect ELISA. 50. Mu.g of the synthetic antigen procalcitonin was dissolved in 10mL of 0.05M phosphate buffer pH9.6, coated in polystyrene 96-well plates, 100. Mu.L/well, and overnight at 4 ℃. The plate was washed three times with PBS (containing 0.05% v/v Tween-20), 100. Mu.L/well with 1% BSA blocking solution in 10mM PBS, blocked at 37℃for 2h, three times with PBS (containing 0.05% v/v Tween-20), 10 days post-third immunization, blood was collected from the tail vein of the mice, and murine immune serum was subjected to 10 with 10mM PBS containing 1% BSA ^-2 ～10 ^-8 Diluting with 96-well plate, adding 100 μL/well 37 deg.C for 1h, washing with PBS (containing 0.05% v/v Tween-20) three times, adding 1:10000-fold diluted horseradish peroxidase-labeled goat anti-mouse IgG (Sigma, INC.), 100 μL/well, and washing with 37 deg.C for 30minAfter that, TMB was developed, 100. Mu.L/well, and protected from light at room temperature for 10min, 50. Mu.L/well 2M H was added ₂ SO ₄ Stopping the reaction, measuring the absorption value at 450nm, taking the serum of the mice before immunization as a negative control, and taking the ratio of the measured value to the control value as a positive judgment value which is more than or equal to 2.1 to determine the titer of the immune serum.

4. Preparation of hybridomas

Serum titers of greater than 1:10 were taken ⁵ 3 days before fusion, synthetic antigen procalcitonin was taken and mixed with an equal volume of PBS, and BALB/c was injected intraperitoneally in an amount of 50. Mu.g/500. Mu.L each for booster immunization. The spleen of the mice is aseptically taken, a spleen cell suspension is prepared, the spleen cell suspension is mixed with a mouse myeloma cell strain SP2/0 in a logarithmic phase at a ratio of 1:1, 1000g of the mixture is centrifuged at room temperature for 5min, the supernatant is discarded, the bottom of a centrifuge tube is flicked by a finger, the sediment is loosened, the centrifuge tube is placed in a water bath at 37 ℃, 50% polyethylene glycol (PEG, MW4000, sigma) which is preserved in the water bath at 37 ℃ is added into the centrifuge tube dropwise while shaking the centrifuge tube while dripping is completed within 1min, the centrifuge tube is left standing for 2min after dripping is completed, the effect of polyethylene glycol is stopped by adding 1mL, 2mL, 3mL, 4mL, 5mL and 10mL of serum-free 1640 medium preheated at 37 ℃ every 1min, the cell mixture is centrifuged at room temperature for 5min, the supernatant is discarded, HAT culture solution (hypoxanthine (H), aminopterin (A) and thymidine (HAT, sigma)) is added to light-resuspend the cells, and the cells are separated into 96-well plates at 200 mu L per well. After three days of culture, the cell fusion was observed, half of HAT medium was changed, and the culture was continued for several days until clone formation, and HT medium (hypoxanthine (H) and thymidine (T) (HT, sigma)) was changed seven days after fusion.

5. Screening of hybridoma cells secreting anti-procalcitonin monoclonal antibodies

The cell culture supernatant was screened by indirect ELISA, positive cloned hybridoma cells with higher titers were selected for subcloning (Table 2), and continuous cloning was performed 2-3 times by limiting dilution until 100% of the cell positive rate was reached, and finally a stable anti-procalcitonin secretion monoclonal antibody cell line, labeled A4D7, and the like, was obtained. And (5) performing liquid nitrogen freezing after amplification culture on the cells with the positive rate reaching 100% after cloning.

TABLE 2 monoclonal antibody screening results

6. Preparation and purification of ascites

Hybridoma cell line A4D7 was grown at 1X 10 ⁶ The abdominal cavity of 8-10 week old BALB/c female mice pretreated with liquid paraffin is injected into the amount of the liquid paraffin, and the ascites is extracted when the abdomen of the mice expands after 10-14 days of feeding observation. Purifying the monoclonal antibody by adopting an affinity chromatography Protein G Sepharose Fast Flow, and determining the purity of the monoclonal antibody by SDS-PAGE, wherein the purity reaches more than 90%.

Example 2 characterization of monoclonal antibody A4D7

1. Determination of antibody concentration: the ascites prepared by hybridoma cells A4D7 and the like is purified to obtain monoclonal antibody A4D7 of procalcitonin and the like, and the monoclonal antibody A4D7 is measured by using a Nanodrop nucleic acid protein measuring instrument manufactured by Thermofisher company, and the concentration of the monoclonal antibody A4D7 is more than 1mg/ml.

2. Identification of antibody subtypes: subtype of hybridoma cell strain is identified by using a mouse monoclonal antibody subtype identification kit of Thermofisher, subtype of A4D7 secretion antibody is IgG1 type, and light chain is kappa chain.

3. Identification of titers of purified antibodies: 50 μg of synthetic procalcitonin was dissolved in 10mL of 0.05M carbonate coating buffer pH9.6, and 96-well plates were added at 100 μl per well overnight at 4deg.C. PBS (containing 0.05% v/v Tween-20) plates were washed three times, blocking with blocking solution (150. Mu.L/well) containing 1% BSA in 10mM PBS, blocking at 37℃for 2h, plates were washed three times with PBS (containing 0.05% v/v Tween-20), 100. Mu.L of purified antibody was added to each well, incubated at 37℃for 1h, PBS (containing 0.05% v/v Tween-20) plates were washed three times, goat anti-mouse IgG polyclonal antibody labeled with horseradish peroxidase was added as secondary antibody, incubated at 37℃for 30min, PBS (containing 0.05% v/v Tween-20) plates were washed three times, 100. Mu.L of TMB was added to each well, developed, incubated at 37℃for 15min, and 2M H was added ₂ SO ₄ The reaction was stopped and the microplate reader was tested at an absorbance of 450 nm.

4. Antibody binding force test:

procalcitonin was diluted to 0.5. Mu.g/mL and 1. Mu.g/mL with 1 XCB, respectively, added to the wells of the ELISA plate in an amount of 100. Mu.L/well, and the wells were multiplexed and allowed to stand at 4℃overnight or at 37℃for 2 hours. The coated microplates were spin-dried, washed once according to the procedure set by the plate washer (AFP procedure), and blocking solution was added in an amount of 200 μl/well, placed in a 37 ℃ incubator for 2 hours, and then placed at 4 ℃ overnight. Before use, taking out the closed microplate from the temperature of 4 ℃, spin-drying, and adding a cleaning solution (1 XPBS-T) to moisten the enzyme-labeled plate; the monoclonal antibody A4D7 of the present invention was pre-diluted to 30. Mu.g/mL with 1 XPBS, and the fold m of pre-dilution was recorded, and then diluted 10-fold, i.e., 3. Mu.g/mL, as the (S1) highest concentration, and then diluted with a 1:3 gradient (diluted in 96 deep well plates), for a total of 8 dilution gradients (S1-S8).

Adding 100 mu L of diluted antibody into a 96-well microplate which is cleanly beaten on absorbent paper, and incubating for 30min at 37 ℃; spin-drying the ELISA plate after incubation, beating on absorbent paper, cleaning the ELISA plate 3 times with a plate washer, and adding 100 μl of 1×PBS into each hole of 1-4 columns; adding 200 mu L of urea treatment solution into each of 5 columns and 6 columns of holes, and incubating for 30min at 37 ℃; spin-drying the ELISA plate after incubation, beating the ELISA plate on absorbent paper, cleaning the ELISA plate 3 times by using a plate washer, adding 100 mu L of GAM-HRP ELISA secondary antibody which is diluted 10000 times by secondary antibody diluent in advance into each hole, and incubating for 30min at 37 ℃; spin-drying the ELISA plate after incubation, beating the ELISA plate on absorbent paper, cleaning the ELISA plate 3 times by using a plate washer, taking TMB color development liquid, adding 100 mu L color development liquid into each hole, and incubating for 5-10min at 37 ℃; after development, 50. Mu.L of stop solution was added to each well. The read at 450nm/630nm was set up on a microplate reader.

ELISA antigen-antibody binding force experiments were tested under the conditions of 0.5 mug/mL and 1 mug/mL antigen coating respectively, data were obtained by testing absorbance OD (FIG. 2), and corresponding polynomial curves were obtained by fitting, the corresponding binding can see significant gradient with the variation of antibody dilution ratio, meanwhile, affinity binding reflected by the two curves under the conditions of 0.5 mug/mL and 1 mug/mL antigen coating shows binding specificity, andreflecting that the concentration corresponding to the binding force of the antibody reaches 6.56E-10mol/L (50% of the highest OD reading under the condition of 0.5 mug/mL antigen coating, namely, when the concentration of the antigen-antibody complex is half of the total concentration, the concentration value K corresponding to the antibody _0.5 ) And 1.28E-09mol/L (50% of the highest OD reading under antigen coating conditions of 1. Mu.g/mL, i.e., the concentration of antigen-antibody complex is half of the total concentration, the corresponding concentration value of the antibody, K) ₁ )。

And (3) calculating binding force: the average OD readings of the multiplex wells at S1-S8 antibody concentrations before and after urea treatment were calculated at 0.5. Mu.g/mL and 1. Mu.g/mL, respectively, of antigen coating. Substituting the read value into a binding force calculation formula:

5. monoclonal antibody pairing screening experiment:

and taking the purified A4D7 monoclonal antibody to complete the coupling work. The monoclonal antibodies are matched with other three procalcitonin monoclonal antibodies, and the clone numbers of the three antibodies are F4B4, A8E5 and C6H1 respectively. 49 clinical samples are detected by using the matched products, and detection results are obtained. Analysis was performed by Bland-Altman curve, with the following results:

by curve analysis, it can be seen that when A4D7 is matched with F4B4 to perform sample detection, the correlation between the detection result and the background value of the serum sample is highest. Therefore, A4D7 and F4B4 are the optimal matching schemes (FIGS. 3, A-C).

6. Antibody stability validation:

the experimental operation method is as follows:

6.1 taking 2mg of antibody A4D7, dividing into 4 pieces of 0.5 mg/branch, and sealing with sealing film.

And 6.2, taking one branch for treatment and coupling to prepare the reagent. The reagent is preserved.

6.3 randomly taking one of the two branches for freezing and storing, and the other branch is stored in a 37 ℃ incubator. The storage time was 2 days (48 hours).

6.4 after the end of storage, the antibody was returned to room temperature.

6.5 preparation of reagents for antibody according to the process. After preparation, three experimental groups were tested using the samples.

Comparison of control preservation mode, cryopreservation and detection results at 37 ℃. The stability of the antibodies and the stability of the reagents prepared using the antibodies both showed good results (fig. 4).

7. Monoclonal antibody A4D7 sequencing

Taking the purified monoclonal antibody A4D7 of procalcitonin prepared by the hybridoma cell A4D7. Sequencing of the light chain variable region and the heavy chain variable region revealed that the amino acid sequences of the light chain and heavy chain of antibody A4D7 are shown as SEQ ID NO. 1 and SEQ ID NO. 2, respectively. The light chain variable region sequences of the above-mentioned targeted procalcitonin antibody are CDR-L1 (RSSDSLLHSNGITYLF), CDR-L2 (QMSALS) and CDR-L3 (AQNLHLPWT), and the heavy chain variable region sequences are CDR-H1 (SDYSWE), CDR-H2 (YIDFRGSTKYNPSLRS) and CDR-H3 (RGSFRY). The antibody with the corresponding variable region sequence has high affinity and good specificity; the corresponding antibody variable regions can thus be used for the development of recombinant antibodies, single chain antibodies, bispecific antibodies, for diagnostic or therapeutic use in the development of related products.

EXAMPLE 3 Procalcitonin lateral flow immunochromatographic reagent Performance test

Immune (fluorescent) microspheres are one of the labeling materials used in immunochromatography detection kits, and are covalently bound to biomacromolecules such as proteins having amine ends by modifying the surface of the microspheres with carboxyl ends and the like. Through the mild coupling combination, the activity of the biological macromolecules can be reserved to the maximum extent, and the immune (fluorescent) microsphere becomes a marking material in the commercial immunochromatography test strip widely used in the market at present.

The lateral flow immunochromatography rapid diagnosis kit is a test paper-based result reporting method suitable for instant detection. The core element is a lateral flow immunochromatographic test strip, which is generally in a narrow strip shape, and the width is generally 4-6 mm, and the length is not more than 6-7 cm. A standard lateral flow immunochromatographic test strip should comprise four main parts, respectively: the main material of the sample pad area is made of cellulose, and the sample pad area is fully immersed into an object to be detected when in use; the primary material of the conjugate pad zone is made of glass fibers, and the conjugate pad zone typically contains (conjugated) antigen or (conjugated) antibody; the main material of the detection area is made of Nitrocellulose (NC) film, and the detection area is mainly provided with a detection line and a quality control line which respectively contain corresponding antibodies; the main material of the absorbent pad area is made of cellulose.

When the lateral chromatographic strip is inserted into the solution to be tested, the solution flows from the sample pad area into the conjugate pad area. When the solution contains the substance to be detected, the substance to be detected will bind to the (conjugated) antigen or (conjugated) antibody of the binding pad area. The (conjugated) antibody or (conjugated) antigen rehydrated by the solution or the complex formed with the sample to be tested will pass through the detection zone (NC membrane) and the absorbent pad zone in sequence under the action of capillary force. At this time, the lateral chromatography test paper will have two results display models, respectively a standard model and a competition model:

when the lateral flow immunochromatographic test strip adopts a standard model (for detecting PCT protein antigens), the detection line (comprising specific antibodies targeting the PCT protein antigens) can only capture the complex of the antigen to be detected and the (conjugated) primary antibody: if the antigen to be detected exists in the solution, the detection line can capture a complex formed by the antigen to be detected and the (coupled) primary antibody, and the (coupled) primary antibody is always captured by the quality control line (comprising the corresponding secondary antibody), so that the detection line and the quality control line have color changes at the moment, and the result is judged to be positive reaction. If the antigen to be detected does not exist in the solution, only the quality control line (comprising the corresponding secondary antibody) can capture the colloidal gold (coupled) primary antibody and generate color change, and at the moment, the quality control line develops color while the detection line does not develop color, and the result is judged to be negative reaction.

When the lateral chromatography test paper adopts a competition model (detecting IgG antibody of targeting PCT protein antigen), the antibody to be detected is combined with (conjugated) PCT protein antigen coated on a binding pad area, and the antibody to be detected and the colloidal gold (conjugated) PCT protein antigen can be captured by a detection line (antibody containing anti-IgG): when the antibody to be detected exists, the antibody can be captured by the detection line, the (coupled) antigen can not be captured by the detection line (because of competitive blocking of the antibody to be detected), and further the color change can not occur, but the quality control line (comprising PCT protein antigen paired antibody) can still capture (coupled) antigen, at the moment, the detection line does not develop color, the quality control line develops color, and the result is judged to be positive reaction; if the antibody to be detected does not exist in the solution, the detection line and the quality control line can both capture (couple) the antigen, at the moment, the detection line and the quality control line can both generate color change, and the result is judged to be negative reaction.

After pairing of antibodies (A4D 7 and F4B 4), the evaluation of the (semi-) quantitative relationship of antibodies targeting the purified procalcitonin protein was performed by the method described above: the quality control product of the targeted procalcitonin antibody (product of Roche antigen) produced by the Huzhou Wasabia gold ligand biotechnology Co-Ltd is adopted to detect the lateral flow immunochromatography rapid detection kit developed by the antibody, and the concentration of the labeled antibody is estimated relatively accurately in a certain concentration interval by utilizing a time-resolved fluorescence immunoassay method on the premise of using a specific instrument (FIC-Q1) and specific chemical labeling of the antibody (the procalcitonin-targeted antibody) (and comparing the quantitative accuracy of the labeled antibody concentration with other homogenization products of other companies). Since the target antigen PCT and the paired antibodies are both purified protein products developed by the company, they can be used to assess the accuracy of quantitative relationships over a range of concentrations. As can be seen from comparison of table 3, the comparison of the antibody concentration estimated by comparing the curve fitted with the quality control Product (QC-Product-based Ab-concentration estimation, or "QC-based Ab-con") with the T/C, the direct measurement of the antibody concentration estimated by the antigen (roche) background (Ag-background-based Ab-concentration estimation, or "Ag-based Ab-con") with the T/C), and the fitting curve derived from the fixed parameters recommended by the finishing box (Product-fixed-model-based Ab-concentration estimation, or "Product-based Ab-con") with the T/C, suggests that the antibody concentration estimation method obtained by the fixed parameters recommended by the finishing box and the antibody concentration estimation method by the quality control Product can maintain a stable linear relationship over a larger concentration range relative to the direct measurement of the antigen background, thereby realizing relatively more accurate quantitative analysis (see fig. 5 for the analysis results of batches, fig. 6).

TABLE 3 correlation analysis Table

^* p＜.05， ^＊＊ p＜.01， ^＊＊＊ p＜.001

While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.

Claims (10)

1. The procalcitonin targeting antibody A4D7 is characterized in that the amino acid sequences of a light chain hypervariable region CDR-L1, a CDR-L2 and a CDR-L3 of the antibody are RSSDSLLHSNGITYLF, QMSALAS and AQNLHLPWT respectively, and the amino acid sequences of a heavy chain hypervariable region CDR-H1, a CDR-H2 and a CDR-H3 of an antibody M1301 are SDYSWE, YIDFRGSTKYNPSLRS and RGSFRY respectively.

2. The antibody of claim 1, wherein the amino acid sequences of the light chain and the heavy chain of the antibody are shown in SEQ ID NO. 1 and SEQ ID NO. 2, respectively.

3. Use of an antibody according to claim 1 or 2 in the preparation of a procalcitonin detection reagent or kit.

4. A procalcitonin detection reagent or kit prepared from the antibody of claim 1 or 2.

5. Use of an antibody according to claim 1 or 2 for the preparation of a procalcitonin immunochromatographic test strip or a kit.

6. Use of an antibody according to claim 1 or 2 for the preparation of a procalcitonin lateral flow immunochromatographic diagnostic kit.

7. The procalcitonin immunochromatography detection test strip is characterized by comprising a sample pad, a combination pad, an NC film, a water absorption pad and a bottom plate, wherein a detection line and a quality control line are arranged on the reaction film, and the sample pad, the combination pad, the NC film and the water absorption pad are sequentially adhered to the bottom plate;

wherein, the binding pad is coated with an immune microsphere coupled antibody F4B4 targeting procalcitonin; the detection line is coated with the antibody of claim 1 or 2, and the quality control line is coated with goat anti-mouse polyclonal antibody;

the amino acid sequences of the light chain and the heavy chain of the antibody F4B4 are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4.

8. The test strip of claim 7, wherein the concentration of antibody A4D7 coated on the conjugate pad is 10-15 μg/mL;

the concentration of the antibody A4D7 coated on the detection line is 1.5-2mg/mL.

9. The test strip of claim 7 or 8, wherein the sample pad and the absorbent pad are made of cellulose, and the binding pad is made of glass fiber.

10. The qualitative and semi-quantitative rapid detection method of procalcitonin is characterized in that the detection method is a double antibody sandwich method, the amino acid sequences of the light chain and the heavy chain of the first antibody are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4, and the second antibody is an antibody as set forth in claim 1 or 2.